Date: 2015-09-08
Type of information: Collaboration agreement
Compound: clinical trial bioinformatics
Company: AstraZeneca (UK) the University of Manchester (UK)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On September 8, 2015, AstraZeneca and The University of Manchester today announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time. Projects will include the development of a new bioinformatics system to capture and integrate clinical trial safety, efficacy, biomarker and drug distribution data in real time, presenting the information in the form of graphs that can be easily interpreted by clinicians to help tailor the treatment for patients. The collaboration will also support new training programmes in clinical research and pharmacokinetic and pharmacodynamic modelling for investigators to understand the distribution and clinical effects of medicines within the body. This collaboration builds on existing scientific collaborations between AstraZeneca and The University of Manchester, ranging from research into novel cancer medicines to progressing treatments for lung cancer, advancing inflammatory research and developing new drug delivery systems.
Financial terms: As part of the collaboration, AstraZeneca will provide a total of £11.5 million to support clinical bioinformatics research led by a dedicated team of investigators within the recently established Centre for Cancer Biomarker Sciences at the Manchester Cancer Research Centre. The research will be carried out in partnership with the state-of-the-art clinical trials unit of The Christie NHS Foundation Trust.
Latest news:
